If your plan has one: Standard prior authorization for Wegovy will be denied Appeals are usually unsuccessful (exclusions are plan design decisions) Alternative coverage pathways may exist (cardiovascular or sleep apnea indications) If your plan excludes weight loss coverage, Wegovy has a cardiovascular indication and Zepbound has a sleep apnea indication
Following semaglutide, numerous anti-obesity drugs have been developed to improve the pharmacological properties of GLP-1 RAs, such as prolonging appetite suppression, increasing potency, or mitigating adverse effects, including gastrointestinal symptoms and lean mass loss [34, 35]
The price we saw on the website matched what we paid at checkout, with no add-on fees at the end
In the brain, it blocks the reward response, she said
Personalized plan: Your provider discusses whether GLP-1 is the right fit and explains what to expect